OBI Pharma, Inc. announced that its antibody-drug conjugate (ADC), OBI-992, has been shortlisted as one of eight finalists for the “2024 Most Promising Clinical Candidate” at the 11th Annual World ADC Awards. This recognition highlights the potential of OBI-992, which targets the TROP2 protein, commonly overexpressed in several cancers. Winners will be announced on November 6, 2024, at the World ADC Conference in San Diego, California.
OBI-992 is currently in phase I/II clinical trials in the U.S. for patients with advanced solid tumors, including gastric and lung cancers. The drug received Orphan Drug Designation from the FDA in August 2024 for treating gastric cancer. Preclinical data suggests that OBI-992 offers enhanced serum stability, a bystander effect capable of killing neighboring cancer cells, and potential resistance to drug tolerance, setting it apart from other TROP2 ADCs.
OBI Pharma sees this recognition as a validation of its innovative approach in the ADC field. The company is committed to advancing OBI-992’s development, aiming to offer more effective treatment options for cancer patients globally.
